Tradestie Institutional Equity Comparison Engine

BHST vs INCR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INCR Overall Edge

INCR Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Intercure Ltd. Ordinary Shares (INCR) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BHST trades at N/M Forward P/E with -18.0% operating margin (+3.8% YoY revenue) versus INCR at 6.2x Forward P/E and 0.0% operating margin (+23.9% YoY). In options structure, BHST sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against INCR sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner INCR
BHST N/M vs INCR 6.2x Fwd P/E
Growth & Margin Winner INCR
Op Margin -18.0% vs 0.0% ยท YoY +3.8% vs +23.9%
Momentum & Technical Winner INCR
1Y -79.4% vs +136.7% ยท 52W Pos 6% vs 47%
Options & Structure Winner INCR
UNCLASSIFIED (N/A IV) vs BREAKDOWN (<1st %ile IV)
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
1M Return -22.62%
1Y Return -79.4%
Forward P/E N/M
Unified AI Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
INCR NASDAQ
Intercure Ltd. Ordinary Shares
Pharmaceutical Preparations
$3.24
-7.16% 1D
Market Cap $45.5M
1M Return -26.86%
1Y Return +136.67%
Forward P/E 6.2x
Unified AI Score
66.8 / 100 BUY
Tech 68.0 Fund 62.0 Flow 58.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BHST -79.4% INCR +136.67% Spread: +221.19 pp (INCR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BHST TTM Op. Margin: -18.0% INCR TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHST vs INCR. Trailing 12-month operating profitability (BHST -18.0% vs INCR 0.0%) and valuation multiples (BHST N/M vs INCR 6.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BHST (0) vs INCR (10)
Institutional Metric BHST INCR Criterion Row Winner
Market Capitalization Scale $29.9M $45.5M Larger Scale INCR
Trailing P/E Ratio Valuation N/M 6.2x Lower Multiple INCR
Forward P/E Ratio Valuation N/M 6.2x Lower Multiple INCR
Revenue Growth (YoY) Growth +3.8% +23.9% Higher Growth INCR
Operating Margin (TTM) Profitability -18.0% 0.0% Higher Margin INCR
Net Profit Margin Profitability -31.2% -13.2% Higher Margin INCR
Return on Equity (ROE) Capital Efficiency -142.5% -9.3% Higher ROE INCR
52-Week Range Position Momentum 6% ($1โ€“$7) 47% ($1โ€“$6) Stronger Trend INCR
Beta / 30D Volatility Risk Regime 0.25ฮฒ ยท 86% Vol 0.07ฮฒ ยท 80% Vol Lower Realized Risk INCR
Unified Institutional Score Composite Signal 58.2 / 100 (HOLD) 66.8 / 100 (BUY) Higher Composite INCR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BHST vs INCR Buy Guide
BHST UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BHST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
INCR BREAKDOWN
59d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live INCR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BHST nor INCR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.